Therapeutic Asset Ratings
3,272 results matching 1 filter
91,583 assets · 7,906 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Olaparib
Rhabdoid Tumor
National Cancer Institute (NCI)
P2
B
(57)
Olaparib
Wilms Tumor
National Cancer Institute (NCI)
P2
B
(57)
Oxodotreotide
Prostate Cancer
National Cancer Institute (NCI)
P2
B
(57)
Palbociclib
Langerhans Cell Histiocytosis
National Cancer Institute (NCI)
P2
B
(57)
Palbociclib
Malignant Glioma
National Cancer Institute (NCI)
P2
B
(57)
Palbociclib
Rectal Carcinoma
National Cancer Institute (NCI)
P2
B
(57)
Palbociclib
Ependymoma
National Cancer Institute (NCI)
P2
B
(57)
Palbociclib
Glioma
National Cancer Institute (NCI)
P2
B
(57)
Palbociclib
Hepatoblastoma
National Cancer Institute (NCI)
P2
B
(57)
Palbociclib
Malignant Germ Cell Tumor
National Cancer Institute (NCI)
P2
B
(57)
Palbociclib
Osteosarcoma
National Cancer Institute (NCI)
P2
B
(57)
Palbociclib
Peripheral Primitive Neuroectodermal Tumor
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Langerhans Cell Histiocytosis
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Malignant Glioma
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Rhabdomyosarcoma
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Ependymoma
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Ewing Sarcoma
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Glioma
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Hepatoblastoma
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Malignant Germ Cell Tumor
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Medulloblastoma
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Neuroblastoma
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Osteosarcoma
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Peripheral Primitive Neuroectodermal Tumor
National Cancer Institute (NCI)
P2
B
(57)
Showing 826 to 850 of 3,272 assets
Previous
Page 34 of 131
Next